As detailed in my profile, I have over 10 years of experience in the pharmaceutical industry (GSK Vaccines, UCB Pharma, Bristol-Myers Squibb). By 1943, Squibb operated the largest penicillin production plant in the world in New Brunswick, New Jersey. In addition to day to day coaching and mentoring, members of Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. 0000006923 00000 n The stock was sold at an average price of $64.21, for a total transaction of $200,270.99. This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, statements relating to goals, plans and projections regarding the companys current and projected financial position, results of operations, market position, product development, share repurchase program and business strategy. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Please speak with your recruiter for more information. These documents will be available at no charge on the SECs website at www.sec.gov. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Rhumba Merger Sub Inc. (Merger Sub) will file with the U.S. Securities and Exchange Commission (SEC). People and Business Resource Groups are provided mentor/mentee learning and development among employees on a global scale. Bristol Myers Squibb Our financial strength, dedicated workforce and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation and position the company for sustained growth., $ amounts in millions, except per share amounts. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. The stock's 50-day moving average price is $64.07 and its 200-day moving average price is $62.55. 0000012839 00000 n Materials related to the call will be available at the same website prior to the conference call. Celestica - Ireland. Available to US-based employeesChange location. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Up to 100% of qualifying tuition costs may be covered, based upon manager discretion and budget. paid time off and holidays- employees are expected to work holidays at times. June 08, 2022 06:59 AM Eastern Daylight Time. 0000012578 00000 n Top 50%. (link). Monday Jan 11, 2021 07:30 AM ET. This was driven by its aforementioned revenue growth, a 330-basis-point. 0000007092 00000 n 0000003062 00000 n Add to iCalendar. hA 04Fq\GczC. Our broad range of benefits opportunities can enrich your total rewards experience and financial readiness to take on whatever is next in your life: Our paid vacation and holidays give you the flexibility to take time off to recharge and return refreshed and invigorated to deliver your best: Theres more to a healthy person than a healthy body. Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.72. Investors and the public can also access the live webcast by dialing in the U.S. toll free 877-502-9276 or international +1 313-209-4906, confirmation code: 2150568. 0000003660 00000 n Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company's pipeline that further progressed the company's portfolio renewal. The basis for our security efforts is to protect our employees, operations and intellectual property. 0000043107 00000 n "The first of the new aircraft will enter service in late-2023, with the bulk to . Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. We expect our contractors and suppliers to comply with all legal and regulatory requirements for the workplace, including health and safety, diversity and human rights. 0000193195 00000 n In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. Usually give off For the year end holidays too! (. The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.1 billion, or $1.83 per share, in the fourth quarter, compared to non-GAAP net earnings of $3.3 billion, or $1.46 per share, for the same period a year ago. FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation, a Bristol-Myers Squibb Company, at 1-888-423-5436. rotating shift 36/48, which involves working all holidays that fall on the schedule. Choosing Your Medical Plan. I am confident in our ability to execute against key milestones in 2022, including three planned first-in-class launches with the fixed dose combination of relatlimab plus nivolumab, mavacamten and deucravacitinib. A REMS program was included in the initial application for mavacamten. Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy. Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Special . Bristol-Myers Squibb bulls will hope to hear the company announce they've not only beaten. The 2022 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in seven European countries from 2-19th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Stress management, well-being, and integrating work with life all determine the energy we bring each day to our work, family and community. 0000011095 00000 n Virtual Benefits Fair. Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. endobj 0000193438 00000 n On-site services depending on location, such as Federal Credit Union, dry cleaning, automobile detailing and massage therapy. We believe in a Total Rewards experience that enriches your life today and engages and empowers you to save, perform, grow, and build toward all of your tomorrows. A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. An effective tax rate of approximately 24% for GAAP and approximately 16.5% for non-GAAP.